Marchina E van der Ende
Overview
Explore the profile of Marchina E van der Ende including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
760
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lungu C, Overmars R, Grundeken E, Boers P, van der Ende M, Mesplede T, et al.
Viruses
. 2023 Nov;
15(11).
PMID: 38005913
Although some individuals with HIV-2 develop severe immunodeficiency and AIDS-related complications, most may never progress to AIDS. Replication-competent HIV-2 isolated from asymptomatic long-term non-progressors (controllers) have lower replication rates than...
2.
Wijting I, Wit F, Rokx C, Leyten E, Lowe S, Brinkman K, et al.
EClinicalMedicine
. 2020 Jan;
17:100210.
PMID: 31891143
Background: Integrase inhibitors (INI) induce a rapid decline of HIV-RNA in plasma and CD4 T-cell recovery in blood. Both characteristics are also associated with immune reconstitution inflammatory syndrome (IRIS). Whether...
3.
Wijting I, Rokx C, Zillikens M, Smits S, de Vries-Sluijs T, Schurink C, et al.
Int J STD AIDS
. 2019 Aug;
30(11):1042-1048.
PMID: 31431155
No abstract available.
4.
Wijting I, Lungu C, Rijnders B, van der Ende M, Pham H, Mesplede T, et al.
J Infect Dis
. 2018 Aug;
218(12):2020-2021.
PMID: 30085047
No abstract available.
5.
Pham H, Labrie L, Wijting I, Hassounah S, Lok K, Portna I, et al.
J Infect Dis
. 2018 Apr;
218(5):698-706.
PMID: 29617824
Background: Dolutegravir (DTG) is an integrase strand-transfer inhibitor (INSTI) used for treatment of human immunodeficiency virus (HIV)-infected individuals. Owing to its high genetic barrier to resistance, DTG has been clinically...
6.
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
Wijting I, Lungu C, Rijnders B, van der Ende M, Pham H, Mesplede T, et al.
J Infect Dis
. 2018 Apr;
218(5):688-697.
PMID: 29617822
Background: A high genetic barrier to resistance to the integrase strand transfer inhibitor (INSTI) dolutegravir has been reported in vitro and in vivo. We describe the dynamics of INSTI resistance-associated...
7.
Snijdewind I, Smit C, Godfried M, Bakker R, Nellen J, Jaddoe V, et al.
PLoS One
. 2018 Jan;
13(1):e0191389.
PMID: 29351561
Background: The benefits of combination anti-retroviral therapy (cART) in HIV-positive pregnant women (improved maternal health and prevention of mother to child transmission [pMTCT]) currently outweigh the adverse effects due to...
8.
Debes J, Pas S, Groothuismink Z, van der Ende M, de Man R, Boonstra A
Liver Int
. 2017 Dec;
38(5):792-796.
PMID: 29285885
Background And Aims: Infection with Hepatitis E virus (HEV) can cause chronic liver disease in immunocompromised hosts. In transplant recipients, the use of certain immunosuppressants and food habits has been...
9.
Op de Coul E, van Sighem A, Brinkman K, van Benthem B, van der Ende M, Geerlings S, et al.
BMJ Open
. 2016 Jan;
6(1):e009688.
PMID: 26729389
Objectives: Early testing for HIV and entry into care are crucial to optimise treatment outcomes of HIV-infected patients and to prevent spread of HIV. We examined risk factors for presentation...
10.
Blonk M, Colbers A, Hidalgo-Tenorio C, Kabeya K, Weizsacker K, Haberl A, et al.
Clin Infect Dis
. 2015 May;
61(5):809-16.
PMID: 25944344
Background: The use of raltegravir in human immunodeficiency virus (HIV)-infected pregnant women is important in the prevention of mother-to-child HIV transmission, especially in circumstances when a rapid decline of HIV...